Clinical determinants of aspirin resistance in diabetes.
Recent studies indicate that not all diabetic subjects benefit from aspirin therapy. Our objective is to characterize diabetic subjects with aspirin resistance using urine thromboxane, and VerifyNow measures. Our results suggest that cardiovascular disease, microalbuminuria, poor diabetes control, and increased waist circumference help identify aspirin resistance in diabetes.
Yassine
Hussein N
HN
Department of Medicine, Division of Endocrinology, University of Arizona Health Sciences Center, Tucson, AZ 85724, USA. hyassine@email.arizona.edu
Davis-Gorman
Grace
G
Stump
Craig S
CS
Thomson
Stephen S
SS
Peterson
Justin
J
McDonagh
Paul F
PF
D000419:Albuminuria / Q000652:urine; D001241:Aspirin / Q000627:therapeutic use*; D015331:Cohort Studies; D003925:Diabetic Angiopathies / Q000097:blood / Q000517:prevention & control* / Q000652:urine; D004351:Drug Resistance; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007333:Insulin Resistance; D008297:Male; D008875:Middle Aged; D009391:Nephelometry and Turbidimetry; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D013929:Thromboxane B2 / Q000031:analogs & derivatives / Q000652:urine; D055105:Waist Circumference
D001241:Aspirin; D006442:Glycated Hemoglobin; D010975:Platelet Aggregation Inhibitors; D013929:Thromboxane B2; C517652:hemoglobin A1c protein, human; C049235:11-dehydro-thromboxane B2